Analysts remain sharply divided on Vertex Pharmaceuticals (VRTX). The stock currently trades around $546, yet price targets span from $350 to $672. Goldman Sachs sits firmly in the bullish camp, maintaining a buy rating and a $653 price target, and recently added Vertex to its highest-conviction list.
The core of Goldman’s bullish thesis rests on Vertex’s distinctive strategic position. The company focuses on innovative therapies for diseases with high unmet need, particularly in rare conditions. Its cystic fibrosis (CF) franchise generates the bulk of revenue. CF patients require lifelong treatment, and with virtually no competition in the space, Vertex enjoys exceptional pricing power. That core business produces stable revenue and earnings, with key patent protections extending into the late 2030s. Rival biotechs have repeatedly tried to develop competing CF therapies, but none have succeeded so far.
Vertex has begun diversifying beyond CF, though newer launches have yet to contribute meaningful revenue. Casgevy, a gene-editing therapy for two rare blood disorders, and Journavx, a treatment for acute pain, are both still in early commercial stages. The recent $10 billion cash acquisition of Crinetics Pharmaceuticals adds further depth. The deal brings Palsonify, an approved therapy for acromegaly, and atumelnant, a phase 3 candidate for congenital adrenal hyperplasia. Vertex estimates the two could generate more than $5 billion in combined peak sales.
Elsewhere in the pipeline, povetacicept for IgA nephropathy has already been submitted for U.S. regulatory approval, with a decision possible by year-end. Inaxaplin targets APOL-1-mediated kidney disease, and multiple additional candidates are in phase 2 and phase 3 development.
Revenue growth has slowed in recent years as Vertex penetrated a large share of the CF market. However, as Journavx and Casgevy scale up and new medicines reach the market, top-line growth could reaccelerate. Clinical and regulatory setbacks remain possible, and a competitor might eventually challenge the CF franchise, but the expanding pipeline helps reduce concentration risk. For long-term investors, Vertex’s entrenched CF monopoly combined with a broadening portfolio presents a compelling picture.
